dr. slamon on the use of trastuzumab and bevacizumab biosimilars in breast cancer
Published 6 years ago • 1K plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
0:55
dr. slamon discusses the future of biosimilars in oncology
-
0:51
dr. jhaveri on the use of trastuzumab biosimilars in breast cancer
-
1:47
the use of trastuzumab and biosimilars in the treatment of breast cancer
-
1:56
dr. schwartzberg on the use of therapeutic biosimilars in breast cancer
-
1:00
dr. kris on the impact of bevacizumab biosimilars in lung cancer
-
1:19
dr. slamon on os results of the monaleesa-3 trial in hr /her2- breast cancer
-
3:38
biosimilar trastuzumab
-
1:12
dr. esteva on trastuzumab biosimilar in breast cancer
-
5:05
anti-her2 mechanisms of approved her2 inhibitors
-
7:57
biosimilar characterization
-
1:03:07
mbc impact series: metastatic lobular breast cancer
-
5:09
the use of biosimilars in her2 breast cancer
-
1:01
dr. brufsky on trastuzumab biosimilars in breast cancer
-
1:30
dr. mcbride on the potential impact of bevacizumab biosimilars in oncology
-
0:59
dr. hope rugo on safety of trastuzumab biosimilar for her2 breast cancer
-
1:00
dr. dang on the significance of the myl-1401o biosimilar in her2-positive metastatic breast cancer
-
1:16
dr. brufsky advises doctors on bevacizumab for breast cancer
-
1:49
dr. esteva on trastuzumab biosimilar in patients with her2 breast cancer
-
1:11
dr. hurvitz on importance of biosimilars in her2 breast cancer
-
1:30
dr. hope rugo on trastuzumab biosimilar in her2-positive breast cancer
-
2:09
dr. esteva on the future of biosimilars in breast cancer
-
16:47
what is needed and what is the role of biosimilars?